Clinical benefits of once-weekly epoetin alfa in anemic patients with colorectal cancer receiving chemotherapy

Journal of Supportive Oncology

Volumn 4, Issue 5, 2006, Pages 243-250

  Chu, Edward ^a,b   Einhorn, Lawrence H ^c   Lefebvre, Patrick ^d  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE CANCER CENTER   (United States)

^c INDIANA UNIVERSITY   (United States)

^d GROUPE D ANALYSE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; HEMOGLOBIN; IRINOTECAN; OXALIPLATIN; RECOMBINANT ERYTHROPOIETIN;

ABDOMINAL PAIN; ANEMIA; ARTICLE; ASTHENIA; BLOOD TRANSFUSION; CANCER RADIOTHERAPY; CLINICAL TRIAL; COHORT ANALYSIS; COLORECTAL CANCER; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DRUG TOLERABILITY; ERYTHROCYTE TRANSFUSION; FATIGUE; FEVER; FUNCTIONAL ASSESSMENT; HEMATOPOIESIS; HUMAN; MEDICAL ASSESSMENT; NAUSEA AND VOMITING; PHYSICAL ACTIVITY; PHYSICAL CAPACITY; QUALITY OF LIFE; RATING SCALE; SCORING SYSTEM; SYMPTOM; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; ANEMIA; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; COLORECTAL NEOPLASMS; EPOETIN ALFA; FATIGUE; HEMOGLOBINS; HUMANS; QUALITY OF LIFE; RETROSPECTIVE STUDIES;

EID: 33646789096     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Ludwig H, Strasser K. Symptomatology of anemia. Semin Oncol 2001;28(2 suppl 7):7-14.
2. Curt GA, Breitbart W, Cella D, et al. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 2000;5:353-360.
3. Vogelzang NJ, Breitbart W, Celia D, et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 1997;34:4-12.
4. Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001;91:2214-2221.
5. Majumdar SR, Fletcher RH, Evans AT. How does colorectal cancer present? Symptoms, duration and clues to location. Am J Gastroenterol 1999;94:3039-3045.
6. Tas F, Eralp Y, Basaran M, et al. Anemia in oncology practice: relation to diseases and their therapies. Am J Clin Oncol 2002;25:371-379.
7. Dunne JR, Gannon CJ, Osborn TM, et al. Preoperative anemia in colon cancer: assessment of risk factors. Am Surg 2002;68:582-587.
8. Dunne JR, Malone D, Tracy JK, Gannon C, Napolitano LM. Perioperative anemia: an independent risk factor for infection, mortality, and resource utilization in surgery. J Surg Res 2002;102:237-244.
9. Shasha D, Homel P. Prevalence, severity and evolution of anemia in colorectal cancer patients receiving radiation therapy with/without chemotherapy: a retrospective analysis. Poster presented at the 2006 American Society of Clinical Oncology Gastrointestinal Cancers Symposium: Multidisciplinary Approaches to the Prevention, Diagnosis, and Therapy of GI Cancers; January 26-28, 2006; San Francisco, California. Abstract 384.
10. Harrison LB, Shasha D, White C, Ramdeen B. Radiotherapy-associated anemia: the scope of the problem. Oncologist 2000;5(suppl 2):1-7.
11. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616-1634.
12. Greco FA, Figlin R, York M, et al. Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer. J Clin Oncol 1996;14:2674-2681.
13. Rougier P, Bugat R, Douillard JY, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997;15:251-260.
14. Zori Comba A, Blajman C, Richardet E, et al. A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients. Eur J Cancer 2001;37:1006-1013.
15. Moehler M, Hoffmann T, Zanke C, et al. Safety and efficacy of outpatient treatment with CPT-11 plus bolus folinic acid/5-fluorouracil as first-line chemotherapy for metastatic colorectal cancer. Anticancer Drugs 2003;14:79-85.
16. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-1047.
17. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomised GERCOR study. J Clin Oncol 2004;22:229-237.
18. Vamvakas L, Kakolyris S, Kouroussis C, et al. Irinotecan (CPI-11) in combination with infusional 5-fluorouracil and leucovorin (de Gramont regimen) as first-line treatment in patients with advanced colorectal cancer: a multicentre phase II study. Am J Clin Oncol 2002;25:65-70.
19. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947.
20. Hoff PM, Ansari A, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001;19:2282-2292.
21. Kalofonos HP, Kardamakis D, Bamias A, et al. Adjuvant chemotherapy using CPT-11, leucovorin plus bolus 5-fluorouracil and radiotherapy in patients with rectal cancer: a feasibility study. Anticancer Res 2003;23:1687-1697.
22. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer:results of a large phase III study. Xeloda Colorectal Cancer Study Group. J Clin Oncol 2001;19:4097-4106.
23. Witzig TE, Silberstein PT, Loprinzi CL, et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 2005;23:2606-2617.
24. Glaspy J, Degos L, Dicato M, Demetri GD. Comparable efficacy of epoetin alfa for anemic cancer patients receiving platinum- and nonplatinum-based chemotherapy: a retrospective subanalysis of two large, community-based trials. Oncologist 2002;7:126-135.
25. Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875-2882.
26. Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 1997;13:63-74.
27. Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998;16:3412-3425.
28. Gough IR, Furnival CM, Schilder L, Grove W. Assessment of the quality of life of patients with advanced cancer. Eur J Cancer Clin Oncol 1983;19:1161-1165.
29. McCormack HM, Horne DJ, Sheather S. Clinical applications of visual analog scales: a critical review. Psychol Med 1998;18:1007-1019.
30. Crawford J, Demetri G, Gabrilove JL, et al. Clinical benefits of epoetin alfa therapy in patients with lung cancer. Clin Lung Cancer 2002;3:180-190.
31. Demetri GD, Gabrilove JL, Blasi MV, Hill RJ Jr, Glaspy J. Benefits of epoetin alfa in anemic breast cancer patients receiving chemotherapy. Clin Breast Cancer 2002;3:45-51.
32. Crawford J, Cella D, Cleeland CS, et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002;95:888-895.
33. Clinical Practice Guidelines in Oncology. Cancer and treatment-related anemia. Available at: http:/www.nccn.org/professionals/physician_gls/PDF/anemia.pdf. Accessed March 28, 2006.
34. Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 2002;24:547-561.
35. Bernhard J, Maibach R, Thurlimann B, Sessa C, Aapro MS. Patients' estimation of overall treatment burden: why not ask the obvious? Swiss Group for Clinical Cancer Research. J Clin Oncol 2002;20:65-72.
36. Patrick DL, Gagnon DD, Zagari MJ, Mathijs R, Sweetenham J. Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa. Epoetin Alfa Study Group. Eur J Cancer 2003;39:335-345.
37. Shasha D, George MJ, Harrison LB. Once-weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Cancer 2003;98:1072-1079.
38. Waltzman R, Croot C, Justice GR, et al. Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapy. Oncologist 2005;10:642-650.
39. Steensma DP, Molina R, Sloan JA, et al. Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer. J Clin Oncol 2006;24:1079-1089.
40. Clinical Practice Guidelines in Oncology. Breast Cancer. Available at: http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf. Accessed March 28, 2006.